Actively Recruiting
MODERN Study Evaluating ctDNA-Guided Immunotherapy with Nivolumab and Relatlimab
Led by National Cancer Institute (NCI) · Updated on 2026-11-04
992
Participants Needed
505
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how measuring circulating tumor DNA ctDNA in blood may help identify patients with urothelial cancer who need additional immunotherapy after surgical removal of the bladder, kidney, ureter, or urethra. This phase IIIII trial studies whether treatments with immunotherapy drugs nivolumab and relatlimab can improve survival and prevent cancer from returning in these patients. Participants are assigned to one of two groups based on their ctDNA test results after surgery. Those with detectable ctDNA receive either nivolumab alone or nivolumab combined with relatlimab intravenously every 28 days for up to 12 cycles. Participants without detectable ctDNA are randomized to receive nivolumab immediately or to undergo ctDNA surveillance and start nivolumab only if ctDNA becomes detectable. Throughout the study, patients undergo tissue and blood collections, imaging scans like CT or MRI, and may have cystoscopy. During the trial, participants are monitored with blood tests, tissue sampling, imaging, and questionnaires to assess cancer recurrence, survival, and quality of life. Researchers measure outcomes such as ctDNA clearance, overall survival, and disease-free survival over up to 5 years after treatment. Safety and side effects are also tracked. Follow-up visits occur regularly after treatment completion to continue monitoring health and disease status.
CONDITIONS
Brief Title
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here